Orthocell clears milestone for US launch of Remplir
Orthocell (ASX:OCC), a Perth-based regenerative medicine company, has successfully completed a pivotal US FDA 510(k) regulatory study for its nerve repair product, Remplir. The study validated Remplir as safe and effective for use in the surgical repair of peripheral nerves, meeting all required endpoints. This achievement paves the way for the submission of a marketing […]
Orthocell clears milestone for US launch of Remplir Read More »